The Plasma Profit Pipeline
Biopharmaceutical leader CSL reported a 14% surge in annual profit, fueled by its plasma division's success. This highlights a growing investment opportunity in companies involved in the plasma-derived therapies market and the broader bioprocessing supply chain.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
CSL's impressive 14% profit surge, driven by its plasma division, signals strong fundamentals across the plasma-derived therapies market. This specialised biologics sector offers resilient demand and significant pricing power, making it an attractive investment theme for those seeking targeted healthcare exposure.
What You Need to Know
This group focuses on the expanding plasma therapies ecosystem, from blood plasma collection to bioprocessing technologies and final medicine development. These companies operate in a specialised market with high barriers to entry and consistent demand for life-saving treatments.
Why These Stocks
Each company was handpicked by professional analysts for their role in the plasma profit pipeline. From established market leaders to innovative suppliers supporting the bioprocessing chain, these stocks represent various opportunities within this growing healthcare segment.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+399.94%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 399.94% over the next year.
Stocks Rated Buy by Analysts
15 of 16 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Life-Saving Market Momentum
Plasma-derived therapies treat rare diseases and critical conditions, creating consistent demand that's largely recession-proof. When a market leader reports 14% profit growth, it signals strength across the entire ecosystem.
Pricing Power Advantage
These specialised biologics command premium prices due to their life-saving nature and high barriers to entry. Companies in this space often enjoy strong margins and pricing flexibility that traditional pharmaceuticals can't match.
Innovation Pipeline Potential
From plasma collection technology to advanced bioprocessing, this sector is ripe with innovation opportunities. Early investors in the right companies could benefit as new therapies and technologies reach the market.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.